Deborah S. Yokoe*

, Steven W. Coon†, Rachel Dokholyan‡, Michael C. Iannuzzi†, Timothy F. Jones§, Sarah Meredith¶, Marisa Moore#, Lynelle Phillips**, Wayne Ray¶, Stephanie Schech††, Deborah Shatin††, and Richard Platt*†‡‡
Author affiliations: *Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; †Henry Ford Health System, Detroit, Michigan, USA; ‡Harvard Pilgrim Health Care, Boston, Massachusetts, USA; §Tennessee Department of Health, Nashville, Tennessee, USA; ¶Center for Education and Research in Therapeutics and Vanderbilt University, Nashville, Tennessee, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA; ††Center for Health Care Policy and Evaluation, Minneapolis, Minnesota, USA; and; ‡‡HMO Research Network Center for Education and Research on Therapeutics, Boston, Massachusetts, USA
Main Article
Table 2
Reasons for meeting pharmacy screening criteria among persons without active tuberculosis (TB)
| Reasons why non-TB cases met screening criteria |
Plan A (%) |
Plan B (%) |
Plan C (%) |
Total (%) |
| Suspected active TB, full course of therapy |
7 (13) |
0 |
8 (9) |
15 (10) |
| Suspected active TB, empiric therapy discontinued |
12 (22) |
0 |
35 (38) |
47 (31) |
| Treatment of latent TB infection |
8 (14) |
3 (43) |
10 (11) |
21 (14) |
| Other mycobacterial infections |
26 (47) |
4 (57) |
33 (36) |
63 (41) |
| Other or unknown |
2 (4) |
0 |
5 (5) |
7 (4) |
| Total |
55 |
7 |
91 |
153 |
Main Article
Top of Page